The Cancer Imaging Core serves ACC investigators with cancer-related clinical trials and translational research that involve imaging biomarkers and/or imaging-related endpoints. The overarching goals of the Core are to facilitate and support the use of high quality, advanced imaging modalities in clinical trials by providing easily accessed, reliable, reproducible, timely and validated imaging data and results in a timely and cost- effective manner. In addition to scientific imaging consultation, the Core provides protocol development services, standardized data acquisition methods for cancer imaging trials, and expert image response assessment analyses. The Core supports investigator access to a variety of cancer imaging methods, both standard clinical imaging studies and novel cancer imaging methods developed by Penn investigators, e.g., cancer imaging biomarker methods. The Core's objectives are to: 1) provide high quality consistent image acquisition processes and image analysis for cancer clinical trials involving imaging endpoints; 2) assist with protocol development, submission and activation of cancer clinical trials that involve imaging modalities; 3) provide scientific consultation to clinical investigators on the most appropriate cancer imaging methods to meet scientific needs; and 4) direct investigators to the appropriate choice of both standard and advanced imaging methodologies in ACC clinical investigations. Users and usage has steadily increased over the current project period, and seven of 11 ACC Programs are actively using the Core services in their scientific studies. The Core's ability to provide cost-effective, consistent, and timely quantitative image response assessment is made possible through new web-based tools. Recent changes include: 1) recruitment of an experienced new Co- Leader, Dr. David Mankoff; 2) expanded and more highly automated services for imaging response assessment and support for advanced imaging methods; 3) expanded capabilities in PET and molecular imaging, and 4) recruitment of seasoned Core staff with experience in cancer imaging core administration and imaging-related regulatory matters. Through its support of both standard imaging in cancer clinical trials and advanced imaging for ACC clinical trials, the Core is poised to lead the ACC into the next generation of clinical and translational research studies guided by quantitative cancer imaging. The current yearly rate of imaging response assessment is over 800 studies per year, involving 57 trials, of which 46 were initiated in the current year. A total of 120 new protocols and 31 different investigators, all of whom are ACC members, used the Core in the reporting period (10/01/13-9/30/14). CCSG support represents 33% of the proposed Core budget with the remaining funding coming from charge backs and other grants/contracts. Additional Institutional support is provided in the form of funding for the development of advanced imaging and image analysis methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-44
Application #
9836819
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Kushner, Carolyn J; Hwang, Wei-Ting; Wang, Shiyu et al. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat 170:45-53
Buljan, Vlado A; Graeber, Manuel B; Holsinger, R M Damian et al. (2018) Calcium-axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes. J Biol Phys 44:53-80
Min, Eun Jeong; Safo, Sandra E; Long, Qi (2018) Penalized Co-Inertia Analysis with Applications to -Omics Data. Bioinformatics :
Chang, Changgee; Kundu, Suprateek; Long, Qi (2018) Scalable Bayesian variable selection for structured high-dimensional data. Biometrics :

Showing the most recent 10 out of 1047 publications